Drug Profile
Research programme: immunotherapeutic oligonucleotides - Alnylam/Tekmira
Alternative Names: Immune stimulatory oligonucleotides - Alnylam/TekmiraLatest Information Update: 04 May 2011
Price :
$50
*
At a glance
- Originator Tekmira Pharmaceuticals Corporation
- Class Oligonucleotides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 04 May 2011 No development reported - Preclinical for Immunological disorders in USA (unspecified route)
- 10 Jan 2007 Preclinical trials in Immunological disorders in USA (unspecified route)